Proton MR spectroscopy for monitoring pathologic changes in the substantia nigra and globus pallidus in Parkinson disease

American Journal of Roentgenology

Volumn 206, Issue 2, 2016, Pages 385-389

  Wu, Gang ^a   Shen, Yi Jian ^b   Huang, Mei Hua ^a   Xing, Zhen ^a   Liu, Ying ^a   Chen, Jin ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Neurosurgical Department   (China)

Author keywords

Globus pallidus; Hoehn Yahr stage; Parkinson disease; Proton MR spectroscopy; Substantia nigra

Indexed keywords

CREATININE; N ACETYLASPARTIC ACID; ASPARTIC ACID; CREATINE; N-ACETYLASPARTATE; PROTON;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GLOBUS PALLIDUS; HISTOPATHOLOGY; HOEHN AND YAHR SCALE; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RETROSPECTIVE STUDY; SUBSTANTIA NIGRA; UNIFIED PARKINSON DISEASE RATING SCALE; ANALOGS AND DERIVATIVES; CHEMISTRY; CLASSIFICATION; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; ASPARTIC ACID; CREATINE; FEMALE; GLOBUS PALLIDUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PARKINSON DISEASE; PROTONS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA;

EID: 84956838859     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.14.14052     Document Type: Article

References (23)

1. Boland DF, Stacy M. The economic and quality of life burden associated with Parkinson?s disease: a focus on symptoms. Am J Manag Care 2012; 18:S168-S175
2. Lees AJ, Hardy J, Revesz T. Parkinson?s disease. Lancet 2009; 373:2055-2066
3. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson?s disease: a review of the evidence. Eur J Epidemiol 2011; 26(suppl 1):S1-S58
4. Muangpaisan W, Hori H, Brayne C. Systematic review of the prevalence and incidence of Parkinson?s disease in Asia. J Epidemiol 2009; 19:281-293
5. Zhang ZX, Roman GC, Hong Z, et al. Parkinson?s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 2005; 365:595-597
6. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-442
7. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson?s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007; 22:41-47
8. Jessen F, Block W, Triber F, et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000; 55:684-688
9. Kantarci K, Jack CR Jr, Xu YC, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer?s disease: a 1H MRS study. Neurology 2000; 55:210-217
10. Lucetti C, Del Dotto P, Gambaccini G, et al. Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson?s disease patients. Neurol Sci 2001; 22:69-70
11. Nie K, Zhang Y, Huang B, et al. Marked N-acetylaspartate and choline metabolite changes in Parkinson?s disease patients with mild cognitive impairment. Parkinsonism Relat Disord 2013; 19:329-334
12. Pagonabarraga J, Gómez-Ansón B, Rotger R, et al. Spectroscopic changes associated with mild cognitive impairment and dementia in Parkinson?s disease. Dement Geriatr Cogn Disord 2012; 34:312-318
13. Gröger A, Chadzynski G, Godau J, Berg D, Klose U. Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson?s disease. Eur Radiol 2011; 21:1962-1969
14. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson?s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181-184
15. Choe BY, Park JW, Lee KS, et al. Neuronal laterality in Parkinson?s disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy. Invest Radiol 1998; 33:450-455
16. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson?s disease. Eur J Neurol 2013; 20:16-34
17. Camilleri A, Vassallo N. The centrality of mitochondria in the pathogenesis and treatment of Parkinson?s disease. CNS Neurosci Ther 2014; 20:591-602 [Epub2014 Apr 8]
18. Firbank MJ, Harrison RM, O'Brien JT. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson?s disease. Dement Geriatr Cogn Disord 2002; 14:64-76
19. Sager TN, Topp S, Torup L, Hanson LG, Egestad B, Muller A. Evaluation of CA1 damage using single-voxel 1H-MRS and un-biased stereology: can non-invasive measures of N-acetyl-asparate following global ischemia be used as a reliable measure of neuronal damage? Brain Res 2001; 892:166-175
20. O'Neill J, Schuff N, Marks WJ Jr, Feiwell R, Aminoff MJ, Weiner MW. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson?s disease. Mov Disord 2002; 17:917-927
21. Clarke CE, Lowery M. Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndrome. Eur J Neurol 2001; 8:573-577
22. Martin WR. Magnetic resonance imaging and spectroscopy in Parkinson?s disease. Adv Neurol 2001; 86:197-203
23. Terakawa H, Nakamura M, Nakamori M, et al. Metabolite changes in the basal ganglia in patients with Parkinson?s disease. Ann Neurol 2000; 42:467